Genmab — September 2019
-
Endda inden for en kort tidshorisont.
-
Kursreaktionen er ligegyldig om end irriterende. Ofa er på vej til at give rigtig mange penge løbende i royalty. Vi skal glæde os over at patienterne får et rigtigt godt alternativ til nuværende behandling og kan leve et væsentligt bedre liv end uden Genmabs/Novartis indsats - jeg nævner ikke GSK her !
-
-
Novel new trial - Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Solid Organ Transplantation
-
Er USA lukket i dag?
-
Jeps..nogle af Genmab´s aktionærer´s veje er uransagelige!
-
Det er en heftig oms og kursen bølger frem og tilbage mellem 1355 og 1375. Må ikke håbe det er et skib i havsnød!
-
The study met the primary endpoint of improving progression free survival (PFS). The regimen resulted in a 37% reduction in the risk of progression or death in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with Kd (HR=0.630; 95% CI: 0.464, 0.854; p=0.0014)
-
Sådan!! Solsen.
-
Du er den fødte Genmab-optimist..:-D
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind